Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients.
OBJECTIVE
To evaluate the efficacy and safety of photodynamic therapy (PDT) for macular circumscribed choroidal hemangioma in Chinese patients.


METHODS
Retrospective, consecutive, noncomparative case series.


METHODS
Twenty-five eyes (25 patients) with macular circumscribed choroidal hemangioma, 18 subfoveal and 7 perifoveal, with vision impairment attributable to subfoveal fluid and retinal detachment underwent visual acuity testing, fundus fluorescein angiography, ultrasonography, and optical coherence tomography (OCT) examinations to evaluate the efficacy and safety of PDT treatment. PDT was performed with a standard concentration of verteporfin and intravenous injection time. Laser was used at 50 J/cm² for 83 seconds on subfoveal and 75 J/cm² for 125 seconds on perifoveal lesions. More than 1 spot was used for large lesions and spots overlapped only outside the fovea.


RESULTS
The mean follow-up time was 35.5 ± 15 months. All patients were treated with 1 session except in 2 subfoveal cases. The mean best-corrected visual acuity (BCVA) increased from 0.09 ± 0.11 to 0.31 ± 0.37 (P < .01) and 11 patients (44%) had their vision improve over 4 lines. The remaining 14 patients (56%) had stabilized vision with the retina reattached. The mean thickness of the hemangioma before the treatment was 3.2 ± 0.9 mm and decreased to 1.3 ± 1.0 mm post treatment (P < .01), with complete regression of tumor in 7 cases (28%).


CONCLUSIONS
PDT with individualized laser parameters for macular circumscribed choroidal hemangioma is effective and safe, leading to improved or stabilized BCVA as a result of tumor shrinkage and the resolution of the subretinal fluid.
Zhang
Yongjin
Y
Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China. yongjinzhang@yahoo.com
Liu
Wei
W
Fang
Yanwen
Y
Qian
Jiang
J
Xu
Gezhi
G
Wang
Wenji
W
Li
Lei
L
Shen
Ying
Y
Gao
Qiaoyun
Q
D000328:Adult; D044466:Asian People / Q000208:ethnology; D002681:China / Q000453:epidemiology; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006391:Hemangioma / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D006801:Humans; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin